Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01901367 · ClinicalTrials.gov registry record · NA

ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients

A NA study of Childhood Acute Lymphoblastic Leukemia in Remission, sponsored by Vanderbilt-Ingram Cancer Center.

Completed
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT01901367: Completed NA study of Childhood Acute Lymphoblastic Leukemia in Remission, sponsored by Vanderbilt-Ingram Cancer Center.

NCT01901367 is a NA study of Childhood Acute Lymphoblastic Leukemia in Remission that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 33 participants, below the 212-participant average among 9 other Childhood Acute Lymphoblastic Leukemia in Remission trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01901367, a NA study of Childhood Acute Lymphoblastic Leukemia in Remission, has completed, sponsored by Vanderbilt-Ingram Cancer Center.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

This randomized pilot phase II trial studies how well nutritional intervention and exercise intervention works in preventing metabolic syndrome in younger patients with acute lymphoblastic leukemia. Nutritional intervention may help weight loss and improve quality of life in patients with acute lymphoblastic leukemia. Exercise may help decrease feelings of being tired caused by cancer, may help improve strength, and may help build up lost muscle tissue. Nutritional intervention plus exercise intervention may be effective at preventing metabolic syndrome.

Primary Outcome

Patients undergo a nutrition and counseling intervention designed to decrease their calorie intake, meet micronutrient recommendations, and participate in an exercise plan. Feasibility is defined as \>50% of patients who complete the intervention

Interventions

  • OTHER quality-of-life assessment
  • BEHAVIORAL exercise intervention
  • DIETARY_SUPPLEMENT nutritional intervention
  • OTHER follow-up care
  • BEHAVIORAL counseling intervention

Study Locations (1)

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2013-05
Est. Completion 2015-09
Phase NA
Vanderbilt-Ingram Cancer Center

189 total trials

What the finished NCT01901367 record still lists

NCT01901367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 212-participant average among 9 other Childhood Acute Lymphoblastic Leukemia in Remission trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Childhood Acute Lymphoblastic Leukemia in Remission appearing as the primary indexed condition, and to 5 interventions - of which quality-of-life assessment is the first listed.

NCT01901367 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT01901367 about?

NCT01901367 is a clinical study titled "ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients". This randomized pilot phase II trial studies how well nutritional intervention and exercise intervention works in preventing metabolic syndrome in younger patients with acute lymphoblastic leukemia. Nutritional intervention may help weight loss and improve quality of life in patients with acute lymp...

What is the current status of trial NCT01901367?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2013-05. Estimated completion is 2015-09.

What conditions does trial NCT01901367 study?

This clinical trial studies the following conditions: Childhood Acute Lymphoblastic Leukemia in Remission.

What interventions are being tested in trial NCT01901367?

The interventions under investigation include: quality-of-life assessment (OTHER), exercise intervention (BEHAVIORAL), nutritional intervention (DIETARY_SUPPLEMENT), follow-up care (OTHER), counseling intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT01901367?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01901367 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Childhood Acute Lymphoblastic Leukemia in Remission

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01901367's enrollment target sits among peer trials

33 8th of 9 higher than 2 of 9 other Childhood Acute Lymphoblastic Leukemia in Remission trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Childhood Acute Lymphoblastic Leukemia in Remission trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01901367, the US trial registry maintained by the National Library of Medicine. NCT01901367 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.